Charcot-Marie-Tooth disease (CMT) is not a form of muscular dystrophy. Although the two conditions can look similar on the surface, causing muscle weakness and wasting, they damage completely different parts of the body. CMT is an inherited peripheral neuropathy, meaning it targets the nerves that carry signals between the brain and the limbs. Muscular dystrophy is a group of inherited diseases that directly attacks muscle tissue itself. The distinction matters because the progression, outlook, and management of each condition are quite different.
Why CMT Gets Confused With Muscular Dystrophy
The confusion is understandable. Both CMT and muscular dystrophy are genetic, both cause progressive muscle weakness, and both tend to affect the legs and arms. People with CMT often notice their calves shrinking over time, sometimes taking on a shape described as an upside-down champagne bottle. That visible muscle wasting looks a lot like what happens in certain muscular dystrophies.
Johns Hopkins Medicine classifies both conditions under the broader umbrella of “neuromuscular disorders,” which covers anything affecting the nerve, the muscle, or the connection between the two. CMT falls under diseases of the peripheral nerve, while muscular dystrophy falls under diseases of the muscle fiber. They share a category the way a flat tire and a broken axle share the category of “car trouble.” The end result (the car doesn’t drive well) may overlap, but the underlying problem is in a completely different part.
What CMT Actually Does to the Body
CMT damages the peripheral nerves, the long cables that run from the spinal cord out to the hands and feet. In the most common form, CMT type 1, a genetic mutation disrupts the insulating layer (myelin) that wraps around nerve fibers. That insulation breaks down, slowing the electrical signals that tell muscles to contract. The body tries to repair the damage by building new insulation, but repeated cycles of breakdown and repair create thick, abnormal layers around the nerve that don’t conduct signals well.
Other forms of CMT damage the nerve fiber itself rather than the insulation, but the end result is similar: the nerve gradually loses its ability to communicate with muscles in the hands and feet. Because the muscles stop receiving proper signals, they weaken and shrink over time. The key point is that the muscles themselves start out healthy. They waste away because the nerves feeding them are failing.
How Muscular Dystrophy Differs
In muscular dystrophy, the nerves work fine. The problem is inside the muscle cells themselves. Genetic mutations cause the body to produce defective or missing structural proteins that muscle fibers need to stay intact. Without those proteins, muscle cells break down with normal use and are gradually replaced by fat and scar tissue. The damage is direct: the muscle fiber is structurally flawed from the start.
This fundamental difference shapes everything about how each condition behaves. Muscular dystrophies like Duchenne, the most severe form, can affect the heart and respiratory muscles and significantly shorten life expectancy. CMT, by contrast, typically does not affect life expectancy at all. It progresses slowly and stays concentrated in the hands, feet, and lower legs because those areas are served by the longest peripheral nerves, which are most vulnerable to damage.
Recognizing CMT Symptoms
CMT affects roughly 1 in 2,500 people, making it the most common inherited neurological disease. Symptoms usually appear in adolescence or early adulthood, though they can start earlier or later. The hallmark signs reflect the nerve-first nature of the disease:
- High foot arches and hammertoes. As small muscles in the foot lose nerve supply, the foot’s shape gradually changes.
- Foot drop. Weakness at the ankle makes it hard to lift the front of the foot, leading to a high-stepping walk and frequent tripping.
- Loss of sensation. Numbness or reduced feeling in the feet and hands develops alongside the weakness. This sensory loss is a major clue that separates CMT from muscular dystrophy, which typically does not affect sensation.
- Calf muscle wasting. The lower legs thin out while the upper legs stay relatively normal, creating the characteristic champagne-bottle appearance.
- Hand weakness. Fine motor tasks like buttoning a shirt or writing become harder as the disease progresses to the hands.
That sensory component is one of the clearest giveaways. If you’re losing both strength and feeling in your extremities, the problem is almost certainly in the nerves rather than the muscles.
How Doctors Tell Them Apart
The diagnostic workup for CMT looks very different from a muscular dystrophy evaluation. A nerve conduction study measures how fast electrical signals travel through peripheral nerves. In CMT type 1, conduction speed is uniformly slowed, a signature finding that points directly to damaged nerve insulation. An EMG (electromyography) test can then show which muscles are affected by inserting a small needle electrode and measuring the electrical activity during rest and contraction.
In muscular dystrophy, doctors often start by checking blood levels of creatine kinase, an enzyme that leaks out of damaged muscle cells. Those levels tend to be dramatically elevated. In CMT, creatine kinase is usually normal or only mildly raised, because the muscle cells aren’t breaking down on their own.
Genetic testing is now the most definitive step for both conditions. A blood test can identify the specific gene mutations responsible for CMT, with the most common being a duplication in the gene that codes for a myelin protein. Confirming the exact mutation also helps predict how the disease will behave and whether other family members are at risk.
Living With CMT
Because CMT damages nerves rather than muscles, treatment focuses on maintaining function and adapting to gradual changes rather than trying to slow muscle destruction. There is currently no cure or drug treatment that reverses nerve damage in CMT, but most people remain mobile and independent throughout their lives.
Physical therapy is the cornerstone of management. Stretching and moderate strengthening exercises help keep joints flexible and maintain the muscle mass that remains. Ankle-foot orthoses (lightweight braces worn inside shoes) can compensate for foot drop and make walking steadier. For more significant foot deformities like severe high arches or hammertoes, surgery can realign bones and tendons to improve stability.
Occupational therapy helps with hand weakness, offering adaptive tools and techniques for daily tasks. Some people find that hand splints help with grip. The slow pace of CMT progression gives most people time to adjust gradually, and life expectancy remains normal. That’s a sharp contrast with severe muscular dystrophies, where cardiac and respiratory complications require ongoing monitoring and can be life-threatening.
The Bottom Line on Classification
CMT and muscular dystrophy sit in different branches of the same broad family of neuromuscular diseases. CMT is a neuropathy: it breaks down nerves, which then causes muscles to weaken secondarily. Muscular dystrophy is a myopathy: it breaks down muscle fibers directly. The muscle wasting in CMT is a downstream consequence of nerve failure, not a primary defect in the muscle itself. Getting the classification right matters because it determines which specialists you see, which tests provide useful information, and what kind of management actually helps.